TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04731467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM-24 and Nivolumab - Dose Escalation
Description: Dose escalation of CM24 with nivolumab in adult patients with selected recurrent or metastatic solid tumors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion
Description: Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion
Description: Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion
Description: Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion
Description: Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab, Nab paclitaxel and Gemcitabine - Expansion
Description: Expansion cohort of nivolumab in combination with nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab and Nal-IRI/5-FU/LV - Expansion
Description: Expansion cohort of nivolumab in combination with Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer
Study: NCT06047444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Dose A Unit/Injection (U/I), Intramuscular (IM) on every 12 weeks during a period of 36 weeks with a total of 4 injections.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Dose B U/I, IM on every 12 weeks during a period of 36 weeks with a total of 4 injections.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 U/I, IM on Day 1 and Week 12 with a total of 2 injections.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 U/I, IM on Day 1 and Week 12 with a total of 2 injections.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum toxin type A
Description: Dose A U/I, IM at Week 24 and Week 36 with a total of 2 injections.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum toxin type A
Description: Dose B U/I, IM at Week 24 and Week 36 with a total of 2 injections.
Study: NCT06330493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCB
Description: Paclitaxel coated PTA balloon catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA
Description: Non-coated FDA cleared standard percutaneous transluminal angioplasty balloon catheter
Study: NCT05728489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765250
Description: BI 765250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765250
Description: BI 765250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765250
Description: BI 765250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765250
Description: BI 765250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765250
Description: BI 765250

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04272034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099318
Description: INCB099318 administered orally in 20 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099318
Description: INCB099318 administered orally in 20 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099318
Description: INCB099318 administered orally in 20 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle.
Study: NCT06627049

Intervention type: OTHER
Intervention: Focus group
Description: Focus group to evaluate the facilitators and barriers to the use of virtual reality.

Intervention type: OTHER
Intervention: Focus group
Description: Focus group to evaluate the facilitators and barriers to the use of virtual reality.

Intervention type: OTHER
Intervention: Implementing facilitating strategies
Description: Implement strategies to facilitate the integration of virtual reality into rehabilitation sessions.

Intervention type: OTHER
Intervention: Implementing facilitating strategies
Description: Implement strategies to facilitate the integration of virtual reality into rehabilitation sessions.

Intervention type: OTHER
Intervention: Focus group
Description: Evaluate the strategies used to facilitate VR implementation.

Intervention type: OTHER
Intervention: Focus group
Description: Evaluate the strategies used to facilitate VR implementation.

Intervention type: OTHER
Intervention: Interviews
Description: Interviews to evaluate the facilitators and barriers to the use of virtual reality.

Intervention type: OTHER
Intervention: Interviews
Description: Evaluate the strategies used to facilitate VR implementation.
Study: NCT06135090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Recovery Program (official title TBD)
Description: See arm description
Study: NCT06432842

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laser Treatment
Description: In the study group, low-dose laser treatment was applied in addition to conventional treatment. Chattanoga Group Therapeutic Laser device was used for laser treatment. Laser treatment was applied to 8 sensitive points around the knee for 1 minute, for a total of 8 minutes. Laser treatment was applied continuously, with a wavelength of 830nm and a power of 6J.
Study: NCT06063278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: l Group Therapy for BN.
Description: 9 to 10 group sessions of 90 to 120min each
Study: NCT06042699

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo tablet
Description: Oral placebo tablet provided as placebo comparator.
Study: NCT05678413

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DVIU with paclitaxel injection
Description: Cystourethroscopy will be performed using a 22 Fr rigid cystoscope to allow for ureteric catheter 3F/a wire to be passed through the stricture and into the urinary bladder. DVIU will be performed by cold-knife incisions at the 12-, 3-, and 9 o'clock positions through the full thickness of the fibrosis to healthier appearing tissue. A 23 Fr Wolf (Vernon Hills, IL) injection scope and a standard injection needle was used to inject 30 mg/5mL of paclitaxel vial, 1.5 mL will be injected along the length of each incision into healthier appearing tissue for a total of 5 mL.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DVIU
Description: DVIU
Study: NCT04855123

Intervention type: OTHER
Group type: OTHER
Intervention: retinal imaging
Description: OCT-angiography, Retinophotography, ocular fundus, Pulsed air tonometer

Intervention type: OTHER
Group type: OTHER
Intervention: paraclinical surveillance
Description: blood and urine sampling, assessment of kidney function with creatinine, protein, albumin levels and CKD-EPI equation)
Study: NCT05048823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visceral Osteopathic Techniques
Description: Generalized Discharge Technique of the Peritoneum and Intestinal Wings, Mobilization of the Cecum, Technique for the Root of the Mesentery, Release of the D1-D2 Angle, Technique for the Sigmoid Colon

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Simulated visceral techniques
Description: Simulated visceral techniques in the region of the gastrointestinal system
Study: NCT05593029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: Tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05949060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Intervention
Description: The compassion intervention is a single-session 40-min intervention in which the participants practiced soothing rhythm breathing (i.e., they are directed to slow their breathing using a five-count inhale and five-count exhale). They will then be provided didactic instruction on compassion, and will then be guided through an experiential compassion practice adapted that encompasses cultivating feelings of compassion for a loved one and then for oneself.
Study: NCT06289257

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D level
Description: Vitamin D level in blood

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D level
Description: Vitamin D level in blood

Intervention type: OTHER
Intervention: Vitamin D receptor
Description: Vitamin D receptor in endometriosis tissue
Study: NCT04910828

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Common foods of varying glycemic indices
Description: Examples of foods of varying glycemic index to be tested include bread, rice, breakfast cereals, starchy vegetables, legumes, fruit and dairy products.
Study: NCT05676294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 5 mg of oral olanzapine one hour prior to ambulatory surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral matched placebo one hour prior to ambulatory surgery
Study: NCT05877014

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaires
Description: EQ-5D-5L and SF-12

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: EQ-5D-5L and SF-12
Study: NCT06345833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1%Tranexamic acid with standard local
Description: 1% TXA mixed with standard local consisting 1/4% lidocaine with 1:100,000 epinephrine with saline as the control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% TXA
Description: 3% TXA on TXA-soaked pledgets applied for 10 minutes with saline as the control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% TXA with local plus 3% TXA-soaked pledgets
Description: 1% TXA with local plus 3% TXA-soaked pledgets with saline as the control.
Study: NCT05877014

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scanner
Description: CT scan at M9 and then at M12 if the humerus is not consolidated at M6

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scanner
Description: CT scan at M9 and then at M12 if the humerus is not consolidated at M6
Study: NCT01343875

Intervention type: PROCEDURE
Intervention: tear of the distal tendon in the biceps muscle
Study: NCT05857306

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olvanil
Description: Nutritional recommendation along with 4 mg Olvanil (1 capsule daily)~Subects within the Intervention group will be provided with a nutritional recommendation along with Olvanil capsules. Subjects will be asked to consume one capsule per day. Every capsule contains: 4 mg Olvanil and 255 mg soy lecithin as excipient

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nutritional recommendation along with 255 mg soy lecithin (1 capsule daily)~Subects within the placebo group will be provided with a nutritional recommendation along with placebo capsules. Subjects will be asked to consume one capsule per day. Every capsule contains: 255 mg soy lecithin
Study: NCT06446388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS31905
Description: Administered as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS31905
Description: Administered as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS31905
Description: Administered as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS31905
Description: Administered as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS31905
Description: Administered as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS31905
Description: Administered as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2, intravenous infusion, D1, up to 8 cycles.
Study: NCT05570292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Domperidone
Description: ultrasound guieded assesment of gastric residual volume will be done 2 h after oral injestion of domperidone tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid
Description: ultrasound guieded assesment of gastric residual volume will be done 2 h after oral injestion of folic acid tablet
Study: NCT05457426

Intervention type: PROCEDURE
Intervention: robotic right hemicolectomy with CME
Description: The distribution of trocars was placed according to the position of Intuitive Surgical Inc. for robotic colectomy. The robot was set to come and dock from theright shoulder of the patient. Three robotic 8-mm trocars (R1, R2 and R3) and two 12-mm trocars (camera and assistant port) were used for the robotic procedure. One working arm carrying a monopolar cautery hook for dissection was located in the left upper quadrant port (R1). The other two working arms carried bipolar forceps in the suprapubic port (R3), and Cadiere's fenestrated forceps in the right lower quadrant port (R2) that was used to keep the superior mesenteric axis in traction. After gentle cephalad traction on the transversemesocolon with the grasp in R2, the assistant grasped the ileocecal valve through the assistant port to put the ileocolic vascular pedicle on tension and the ileocolic vessels were identified and lifted up with R3.
Study: NCT06312267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioelectric dressing
Description: Participants randomized into the experimental arm will have a bioelectric dressing applied 3 days before surgery, and 3 days post-surgery.
Study: NCT05005741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beinaglutide
Description: Patients received beinaglutide subcutaneously three times a day for 16 weeks, the dose of beinaglutide escalate from 0.06mg to 0.2mg per 3-7 days according to subject's specific situation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Patients received 1.5mg Dulaglutide subcutaneously once-weekly for 16 weeks.
Study: NCT04704999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tafenoquine
Description: Tafenoquine will be given as 100mg coated tablets. Tablets will be given based on weight bands.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tafenoquine
Description: Tafenoquine will be given as 100mg coated tablets. Tablets will be given based on weight bands.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Chloroquine will be given as daily dose over 3 days (25mg/kg total dose divided 10/10/5mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Chloroquine will be given as daily dose over 3 days (25mg/kg total dose divided 10/10/5mg/kg)
Study: NCT04884802

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tight pressure management
Description: Norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Routine pressure management
Description: ACEIs, ARBs, and/or calcium channel blockers can be given the morning of surgery if deemed appropriate by the attending anesthesiologist. Intraoperative blood pressure will be managed per clinical routine.
Study: NCT05606965

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Egg-based Quadrivalent Influenza Vaccine
Description: Sterile suspension for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted Quadrivalent Influenza Vaccine
Description: Sterile injectable emulsion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Influenza Vaccine
Description: Sterile suspension for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1045
Description: Sterile liquid for injection
Study: NCT04722354

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperinsulemic euglycemic clamp
Description: Following a 12-hour overnight fast at the CRU (including abstinence from caffeine containing foods and beverages), insulin sensitivity will be measured using the criterion method of the euglycemic clamp. Participants will have not performed vigorous physical activity for at least the previous 24 h, and be free of acute illness for the prior 2 weeks. An intravenous catheter will be placed in an antecubital vein for subsequent insulin (40 mU/m2-min) and glucose infusions and for stable isotope (6, 6-2H2) infusions to measure insulin sensitivity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hyperinsulemic euglycemic clamp
Description: Following a 12-hour overnight fast at the CRU (including abstinence from caffeine containing foods and beverages), insulin sensitivity will be measured using the criterion method of the euglycemic clamp. Participants will have not performed vigorous physical activity for at least the previous 24 h, and be free of acute illness for the prior 2 weeks. An intravenous catheter will be placed in an antecubital vein for subsequent insulin (40 mU/m2-min) and glucose infusions and for stable isotope (6, 6-2H2) infusions to measure insulin sensitivity.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Biopsy
Description: One biopsy taken prior to clamp and a second biopsy taken 30-45 min after the start of the clamp. A biopsy of the Vastus Lateralis muscle will be performed on the leg/thigh using the Bergstrom technique.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Muscle Biopsy
Description: One biopsy taken prior to clamp and a second biopsy taken 30-45 min after the start of the clamp. A biopsy of the Vastus Lateralis muscle will be performed on the leg/thigh using the Bergstrom technique.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral abscisic acid (ABA)
Description: Those in this group will receive ABA (95 µg ABA and 300 mg of corn starch)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Those in this group will receive placebo (300 mg cornstarch)
Study: NCT06420700

Intervention type: PROCEDURE
Intervention: Combined gastric mucosal ablation with endoscopic sleeve gastroplasty
Description: Combined gastric mucosal ablation with endoscopic sleeve gastroplasty in the treatment of adults with obesity
Study: NCT06535854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevail DCB
Description: The Prevail Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR) and to treat de novo lesions in small vessel disease.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevail DCB
Description: The Prevail Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR) and to treat de novo lesions in small vessel disease.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Agent DCB
Description: The Agent Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR).
Study: NCT05527769

Intervention type: PROCEDURE
Intervention: mastectomy + immediate breast reconstruction
Description: pre- or retro pectoral prosthesis

Intervention type: PROCEDURE
Intervention: mastectomy + immediate breast reconstruction
Description: pre- or retro pectoral prosthesis
Study: NCT04704999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether 20 mg-Lumefantrine 120 mg
Description: Artemether-lumefantrine will be given twice daily over 3 days. Whole tablets will be given based on weight bands.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether 20 mg-Lumefantrine 120 mg
Description: Artemether-lumefantrine will be given twice daily over 3 days. Whole tablets will be given based on weight bands.
Study: NCT04846751

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TYPE OF EXERCISE (OR REST)
Description: continous exercise in normal temperature, continous exercise in hot environment, intervallic exercise in normal temperature.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TYPE OF EXERCISE (OR REST)
Description: continous exercise in normal temperature, continous exercise in hot environment, intervallic exercise in normal temperature.
Study: NCT05249231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: Previous studies have recommended silver diamine fluoride (SDF) to exert a preventive result in managing early childhood caries ECC. However, no well-designed clinical trials have yet been performed to study the effect of SDF on caries prevention. The result is useful in arresting early childhood caries (ECC)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hall technique
Description: The first report on the Hall Technique published in 2007 by a general dental practitioner from Aberdeen/Scotland, Dr. Norna Hall. Dr. Hall used PMCs to restore carious primary molars rather than using the standard technique, placed them using a simplified method